NYSE:BHVNBiohaven Pharmaceutical Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Biohaven Pharmaceutical Holding Co Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $62.16 +2.76 (+4.65 %) (As of 08/13/2020 04:00 PM ET) Add Compare Share Today's Range$60.50Now: $62.16▼$63.4850-Day Range$59.79MA: $69.78▼$76.3952-Week Range$26.56Now: $62.16▼$78.75Volume624,355 shsAverage Volume907,025 shsMarket Capitalization$3.71 billionP/E RatioN/ADividend YieldN/ABeta1.31 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias. The company also offers Troriluzole that is in phase II/III clinical stage for obsessive compulsive disorders, Alzheimer diseases, and generalized anxiety disorders; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000, a product that has completed phase I clinical trial for neuropsychiatric disorders; and Verdiperstat, a product that is in is in phase III trial for neuro-inflammation. Biohaven Pharmaceutical Holding Company Ltd. was founded in 2013 and is headquartered in New Haven, Connecticut.Read More Beat the Market (BTM) Rank™ 4.4 Analyst's Opinion Consensus RatingBiohaven Pharmaceutical has received a consensus rating of Buy. The company's average rating score is 2.82, and is based on 9 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $78.90, Biohaven Pharmaceutical has a potential upside of 26.9% from its current price of $62.16.Amount of Analyst CoverageBiohaven Pharmaceutical has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.4 Community Rank Outperform VotesBiohaven Pharmaceutical has received 310 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBiohaven Pharmaceutical has received 346 “underperform” votes. (Add your “underperform” vote.)Community SentimentBiohaven Pharmaceutical has received 52.74% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Biohaven Pharmaceutical and other stocks. Vote “Outperform” if you believe BHVN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BHVN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBiohaven Pharmaceutical does not currently pay a dividend.Dividend GrowthBiohaven Pharmaceutical does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Biohaven Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $59,372,838.00 in company stock.Percentage Held by InsidersOnly 19.10% of the stock of Biohaven Pharmaceutical is held by insiders.Percentage Held by Institutions97.15% of the stock of Biohaven Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Biohaven Pharmaceutical are expected to grow in the coming year, from ($9.47) to ($7.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biohaven Pharmaceutical is -5.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biohaven Pharmaceutical is -5.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 4.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.69 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:BHVN Previous SymbolNASDAQ:BHVN CUSIPN/A CIK1689813 Webwww.biohavenpharma.com Phone203-404-0410Debt Debt-to-Equity RatioN/A Current Ratio3.89 Quick Ratio3.85Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.14) per share Price / Book-444.00Profitability EPS (Most Recent Fiscal Year)($10.91) Net Income$-528,800,000.00 Net MarginsN/A Return on Equity-694.23% Return on Assets-123.18%Miscellaneous Employees63 Outstanding Shares59,686,000Market Cap$3.71 billion Next Earnings Date11/6/2020 (Estimated) OptionableOptionable $62.16 +2.76 (+4.65 %) (As of 08/13/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive BHVN News and Ratings via Email Sign-up to receive the latest news and ratings for BHVN and its competitors with MarketBeat's FREE daily newsletter. Biohaven Pharmaceutical (NYSE:BHVN) Frequently Asked Questions How has Biohaven Pharmaceutical's stock been impacted by COVID-19? Biohaven Pharmaceutical's stock was trading at $39.46 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BHVN stock has increased by 57.5% and is now trading at $62.16. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Biohaven Pharmaceutical? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biohaven Pharmaceutical in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Biohaven Pharmaceutical. When is Biohaven Pharmaceutical's next earnings date? Biohaven Pharmaceutical is scheduled to release its next quarterly earnings announcement on Friday, November 6th 2020. View our earnings forecast for Biohaven Pharmaceutical. How were Biohaven Pharmaceutical's earnings last quarter? Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) announced its earnings results on Monday, August, 10th. The company reported ($2.55) earnings per share for the quarter, beating the consensus estimate of ($2.78) by $0.23. The firm earned $9.70 million during the quarter, compared to the consensus estimate of $7.43 million. During the same quarter in the previous year, the firm earned ($2.35) EPS. View Biohaven Pharmaceutical's earnings history. What price target have analysts set for BHVN? 11 analysts have issued 1 year target prices for Biohaven Pharmaceutical's stock. Their forecasts range from $41.00 to $109.00. On average, they expect Biohaven Pharmaceutical's share price to reach $78.90 in the next twelve months. This suggests a possible upside of 26.9% from the stock's current price. View analysts' price targets for Biohaven Pharmaceutical. Has Biohaven Pharmaceutical been receiving favorable news coverage? Media stories about BHVN stock have been trending extremely negative this week, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Biohaven Pharmaceutical earned a media sentiment score of -4.1 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near term. View the latest news about Biohaven Pharmaceutical. Are investors shorting Biohaven Pharmaceutical? Biohaven Pharmaceutical saw a increase in short interest during the month of January. As of January 31st, there was short interest totaling 7,970,000 shares, an increase of 23.0% from the January 15th total of 6,480,000 shares. Based on an average daily volume of 908,300 shares, the days-to-cover ratio is currently 8.8 days. Approximately 17.0% of the shares of the stock are short sold. View Biohaven Pharmaceutical's Short Interest. Who are some of Biohaven Pharmaceutical's key competitors? Some companies that are related to Biohaven Pharmaceutical include Catalent (CTLT), Teva Pharmaceutical Industries (TEVA), Sarepta Therapeutics (SRPT), GRIFOLS S A/S (GRFS), GALAPAGOS NV/S (GLPG), Elanco Animal Health (ELAN), Dr.Reddy's Laboratories (RDY), Ono Pharmaceutical (OPHLF), Mylan (MYL), Ascendis Pharma A/S (ASND), Ionis Pharmaceuticals (IONS), Perrigo (PRGO), Emergent Biosolutions (EBS), Jazz Pharmaceuticals (JAZZ) and ACADIA Pharmaceuticals (ACAD). View all competitors. What other stocks do shareholders of Biohaven Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven Pharmaceutical investors own include AbbVie (ABBV), NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Crispr Therapeutics (CRSP), QUALCOMM (QCOM), Sarepta Therapeutics (SRPT), Abbott Laboratories (ABT) and Netflix (NFLX). Who are Biohaven Pharmaceutical's key executives? Biohaven Pharmaceutical's management team includes the following people: Dr. Vladimir Coric, CEO & Director (Age 48)Mr. James Engelhart, Chief Financial Officer & Treasurer (Age 55)Dr. Charles Conway, Chief Scientific Officer (Age 57)Mr. Clifford Bechtold, Chief Operating OfficerMr. Matthew DeLawder, Director of Accounting When did Biohaven Pharmaceutical IPO? (BHVN) raised $124 million in an initial public offering on Thursday, May 4th 2017. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital served as the underwriters for the IPO and William Blair and Needham & Company were co-managers. What is Biohaven Pharmaceutical's stock symbol? Biohaven Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN." Who are Biohaven Pharmaceutical's major shareholders? Biohaven Pharmaceutical's stock is owned by many different institutional and retail investors. Top institutional shareholders include Marshall Wace LLP (4.27%), FMR LLC (2.31%), Bank of New York Mellon Corp (1.35%), Columbus Circle Investors (0.86%), Emerald Advisers LLC (0.85%) and Emerald Mutual Fund Advisers Trust (0.75%). Company insiders that own Biohaven Pharmaceutical stock include Declan Doogan, Elyse Stock, Eric Aguiar, Gregory Bailey, James Engelhart, John Tilton, John W Childs, Julia P Gregory, Kimberly Gentile, Robert Berman and Vlad Coric. View institutional ownership trends for Biohaven Pharmaceutical. Which major investors are selling Biohaven Pharmaceutical stock? BHVN stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, C WorldWide Group Holding A S, Nicholas Investment Partners LP, Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, State of Wisconsin Investment Board, Marshall Wace LLP, and Pier Capital LLC. Company insiders that have sold Biohaven Pharmaceutical company stock in the last year include Declan Doogan, Elyse Stock, Eric Aguiar, Gregory Bailey, James Engelhart, John Tilton, John W Childs, Kimberly Gentile, and Robert Berman. View insider buying and selling activity for Biohaven Pharmaceutical. Which major investors are buying Biohaven Pharmaceutical stock? BHVN stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Columbus Circle Investors, Federated Hermes Inc., Bank of New York Mellon Corp, Rhenman & Partners Asset Management AB, Thrivent Financial for Lutherans, First Trust Advisors LP, and International Biotechnology Trust PLC. Company insiders that have bought Biohaven Pharmaceutical stock in the last two years include Gregory Bailey, James Engelhart, John W Childs, and Vlad Coric. View insider buying and selling activity for Biohaven Pharmaceutical. How do I buy shares of Biohaven Pharmaceutical? Shares of BHVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Biohaven Pharmaceutical's stock price today? One share of BHVN stock can currently be purchased for approximately $62.16. How big of a company is Biohaven Pharmaceutical? Biohaven Pharmaceutical has a market capitalization of $3.71 billion. The company earns $-528,800,000.00 in net income (profit) each year or ($10.91) on an earnings per share basis. Biohaven Pharmaceutical employs 63 workers across the globe. What is Biohaven Pharmaceutical's official website? The official website for Biohaven Pharmaceutical is www.biohavenpharma.com. How can I contact Biohaven Pharmaceutical? Biohaven Pharmaceutical's mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The company can be reached via phone at 203-404-0410. This page was last updated on 8/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
